Cognition Therapeutics, Inc. (CGTX)

1.9900 +0.0600 (+3.11%) At close: 04:00PM EDT

Cognition Therapeutics, Inc.

2500 Westchester Ave.
Purchase, NY 10577
United States
412 481 2210
https://www.cogrx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 25

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Lisa Ricciardi	CEO, President & Director	854.15k	N/A	1960
Mr. John Brendan Doyle	Chief Financial Officer	414.88k	N/A	1977
Dr. Anthony O. Caggiano M.D., Ph.D.	Chief Medical Officer and Head of R&D	616.27k	N/A	1970
Dr. Steven A. Weissman Ph.D.	VP & Head of CMC	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Corporate Governance

Cognition Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.